Current State of Personalized Genitourinary Cancer Radiotherapy in the Era of Precision Medicine
Open Access
- 7 May 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
Abstract
Radiation therapy plays a crucial role for the management of genitourinary malignancies, with technological advancements that have led to improvements in outcomes and decrease in treatment toxicities. However, better risk-stratification and identification of patients for appropriate treatments is necessary. Recent advancements in imaging and novel genomic techniques can provide additional individualized tumor and patient information to further inform and guide treatment decisions for genitourinary cancer patients. In addition, the development and use of targeted molecular therapies based on tumor biology can result in individualized treatment recommendations. In this review, we discuss the advances in precision oncology techniques along with current applications for personalized genitourinary cancer management. We also highlight the opportunities and challenges when applying precision medicine principles to the field of radiation oncology. The identification, development and validation of biomarkers has the potential to personalize radiation therapy for genitourinary malignancies so that we may improve treatment outcomes, decrease radiation-specific toxicities, and lead to better long-term quality of life for GU cancer survivors.This publication has 146 references indexed in Scilit:
- Mapping patterns of nodal metastases in seminoma: Rethinking radiotherapy fieldsRadiotherapy and Oncology, 2013
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohortBritish Journal of Cancer, 2012
- Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSAScience Translational Medicine, 2011
- Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective studyThe Lancet Oncology, 2011
- MRE11 Expression Is Predictive of Cause-Specific Survival following Radical Radiotherapy for Muscle-Invasive Bladder CancerCancer Research, 2010
- Clinical Value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Bladder CancerJournal of Clinical Oncology, 2010
- Multimodality Magnetic Resonance Imaging of Prostate CancerJournal of Endourology, 2010
- Mechanisms of Disease: the epidemiology of bladder cancerNature Reviews Endocrinology, 2006
- Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptomeOncogene, 2005